J&J charts $2.58-B course
Johnson & Johnson has struck a strategic agreement with Sail Biomedicines to advance treatments for immune-mediated diseases while securing an exclusive option to acquire the biotech company for $2.58 billion.
Under the deal, J&J will make $785 million in initial payments, including a $465-million equity investment, with another $140 million tied to development milestones.
The partnership will focus on Sail’s in vivo CAR-T platform, with the potential to expand the technology across additional therapeutic targets.
J&J also completed its $1-billion acquisition of Firefly Bio, adding the biotech company’s Firelink DAC platform for KRAS-driven tumors to its oncology pipeline.
A traditional dish called zongzi is served during China’s Dragon Boat Festival, which falls in June. It is a rice…
Divina credited the firm’s achievements to its members, thanking them for their ‘hard work, dedication, teamwork, and…
‘Sec. Vince Dizon, please explain how this finding of your own team should not be flagged as a ghost project in Taguig.’
